Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1130 Carcinoma, Non-Small-Cell Lung 719 Neoplasms 547 Prostatic Neoplasms 506 Colorectal Neoplasms 439 Multiple Myeloma 338 Lung Neoplasms 310 Neoplasm Metastasis 290 Leukemia, Myeloid, Acute 263 Stomach Neoplasms 248 Carcinoma, Hepatocellular 246 Ovarian Neoplasms 225 Rectal Neoplasms 211 Colonic Neoplasms 204 Lymphoma, Follicular 200 Lymphoma 199 Leukemia 190 Uterine Cervical Neoplasms 181 Head and Neck Neoplasms 174 Pancreatic Neoplasms 172 Lymphoma, Non-Hodgkin 167 Leukemia, Lymphocytic, Chronic, B-Cell 166 Lymphoma, Large B-Cell, Diffuse 163 Recurrence 161 Melanoma 158 Precursor Cell Lymphoblastic Leukemia-Lymphoma 154 Squamous Cell Carcinoma of Head and Neck 147 Pain 141 Urinary Bladder Neoplasms 139 Brain Neoplasms 133

Interventions

Cholecalciferol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Vitamin D3 × Clear all

NCT03389659 2018-01-03

XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown

Vitamin D3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡